StockData
Equillium, Inc. logo

Equillium, Inc. (EQ) stock

EQNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$1.10−0.11 (-9.09%)

Close on Nov 18, 2026Market cap $69.75MP/E –Yield –

Equillium free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Equillium's free cash flow for the twelve months ending Jun 30, 2026 was -$20.09M. For fiscal 2025 it was -$22.79M. The highest annual figure on record is -$7.56M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.79M–
FY2024Dec 31, 2024-$19.11M–
FY2023Dec 31, 2023-$21.83M–
FY2022Dec 31, 2022-$9.01M–
FY2021Dec 31, 2021-$32.14M–
FY2020Dec 31, 2020-$24.83M–
FY2019Dec 31, 2019-$23.02M–
FY2018Dec 31, 2018-$7.56M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.18M–
Q1 FY2026Mar 31, 2026-$4.30M–
Q4 FY2025Dec 31, 2025-$3.18M–
Q3 FY2025Sep 30, 2025-$8.43M–
Q2 FY2025Jun 30, 2025-$3.01M-551.0%
Q1 FY2025Mar 31, 2025-$8.17M–
Q4 FY2024Dec 31, 2024-$3.30M–
Q3 FY2024Sep 30, 2024-$7.66M-127.6%
Q2 FY2024Jun 30, 2024$668.00K–
Q1 FY2024Mar 31, 2024-$8.82M–
Q4 FY2023Dec 31, 2023-$5.70M–
Q4 FY2022Dec 31, 2022$27.72M–
Q3 FY2022Sep 30, 2022-$13.07M–
Q2 FY2022Jun 30, 2022-$11.31M–
Q1 FY2022Mar 31, 2022-$12.36M–
Q4 FY2021Dec 31, 2021-$10.13M–
Q3 FY2021Sep 30, 2021-$7.04M–
Q4 FY2020Dec 31, 2020-$8.28M–
Q3 FY2020Sep 30, 2020-$5.08M–
Q2 FY2020Jun 30, 2020-$5.08M–
Q1 FY2020Mar 31, 2020-$6.39M–
Q4 FY2019Dec 31, 2019-$9.05M–
Q3 FY2019Sep 30, 2019-$4.70M–
Q2 FY2019Jun 30, 2019-$4.80M–
Q1 FY2019Mar 31, 2019-$4.48M–
Q4 FY2018Dec 31, 2018-$3.84M–
Q3 FY2018Sep 30, 2018-$1.65M–
Q2 FY2018Jun 30, 2018-$1.19M–
Q1 FY2018Mar 31, 2018-$894.00K–

More Equillium figures

See a number that looks wrong?